DENVER, June 9 /PRNewswire-FirstCall/ -- Accelr8 Technology Corporation
(Amex: AXK) and SCHOTT Nexterion (SCHOTT JENAer GLAS GmbH, Jena, Germany)
announced today the signing of a new supply agreement for Nexterion(R) Slide
HS microarray slides using Accelr8's OptiChem(R) surface chemistry. The two
companies also expanded a previous supply agreement for Accelr8 to produce
Nexterion(R) Slide H for SCHOTT.
Accelr8 has been manufacturing Slide HS for SCHOTT since October, 2004.
Under the new agreement Accelr8 will extend production through December, 2005.
SCHOTT also has a right during 2005 to enter into negotiations for an
exclusive manufacturing and distribution license, similar to the Slide H
agreement signed November 4, 2004.
Under a prior supply agreement for Slide H, Accelr8 fulfilled the terms as
planned, but Nexterion sales exceeded forecast. Therefore Nexterion requested
an extension for more products while Nexterion's own production line ramps up.
According to David Howson, Accelr8's president, "under the two agreements
we estimate that product revenues from Nexterion to Accelr8 will total
approximately $150,000 for the remainder of this calendar year."
The ongoing revenues from Slide H and Slide HS production and licensing
occur in parallel with Accelr8's primary business focus in developing the
BACcelr8r(TM) rapid bacterial analysis system. The company intends the
BACcelr8r to become the world's first diagnostic system to provide complete
bacterial antibiotic resistance strain identification in 8 hours or less.
Conventional culturing typically delays lab results from one to three days,
which is inadequate for best management of rapidly progressing, life-
threatening infections in critically ill patients.
Microarraying techniques allow researchers to study massive numbers of
genes and proteins in parallel. The technology is based on placing thousands
of different types of biomolecules onto a surface such as a glass microarray
slide. Microarraying has already had a major impact in fields ranging from
cancer research to agriculture, and is rapidly moving from a discovery
research tool to broader applications in medical diagnostics. Accelr8's
OptiChem coating licensed by SCHOTT Nexterion provides unique performance
advantages that help to make SCHOTT's slides an enabling component of next
"We're very pleased at the market's response to Slide H and now initial
acceptance of Slide HS by a significant industrial customer," said Dr. Lutz
Wehmeier, SCHOTT Nexterion's General Manager. "As part of Nexterion's
comprehensive microarraying product line for DNA as well as protein
applications, we value Accelr8's innovative coating technology in advancing
the performance and adaptability of microarray analysis."
The HS slide provides a streptavidin surface, which is a type of protein
pre-attached to the slide, instead of a chemical reaction linker. The new
coating provides a very uniform surface to maximize detection sensitivity.
Streptavidin is a natural bacterial protein that forms an extremely strong and
specific bond with biotin, a small vitamin molecule, which is widely used as a
molecular linker for proteins, DNA, and other molecules. Streptavidin and
biotin make a popular molecular construction set for building analytical
"Accelr8's Slide HS technology is important because of the wide
familiarity and easily-available commercial kits for binding biotin to the
scientist's target materials, something that all virtually all biomedical
scientists know how to do and feel comfortable with," said Howson. "It's the
easy route -- like a biochemical Lego(R) set -- to assay design."
Accelr8 Technology Corporation (www.accelr8.com) is a developer of
innovative materials and instrumentation for advanced applications in medical
instrumentation, basic research, drug discovery, and bio-detection. In
addition to its microarraying products, Accelr8 is also developing a rapid
clinical pathogen platform, the BACcelr8r(TM), based on its innovative surface
coatings, assay processing, and detection technologies.
SCHOTT (www.schott.com) is an international technology-driven group that
sees its core purpose as the lasting improvement of living and working
conditions through special materials, components and high-tech solutions. Its
main areas of focus are the household appliances industry, optics and
electronics, pharmaceuticals and renewable energies. Schott has a presence in
close proximity to its customers through highly efficient production and sales
companies in all its major markets. It has 18,500 employees producing
worldwide sales of 2 billion euros. The company's technological and economic
expertise is closely linked with its social and ecological responsibility.
The division SCHOTT Nexterion Microarray Solutions
(www.schott.com/nexterion) is specialized in high quality microarray products.
As such, the company develops and markets a wide range of coated and uncoated
glass substrates for DNA and protein microarraying under the brand
Nexterion(R). SCHOTT Nexterion continuously expands its product portfolio and
has several innovative products and services in the development pipeline.
SOURCE Accelr8 Technology Corporation